Larotrectinib Bayer, Larotrectinib Bayer, Larotrectinib Bayer
20290
Phase 2 small_molecule active
Quick answer
Larotrectinib Bayer, Larotrectinib Bayer, Larotrectinib Bayer for Solid tumors harboring NTRK fusion is a Phase 2 program (small_molecule) at Bayer AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer AG
- Indication
- Solid tumors harboring NTRK fusion
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active